Neoadjuvant treatment of breast cancer

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.3K citations

Breast Oncology, Oncology, Immunology +7

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

M Baum, Aman U. Budzar, J Cuzick et al. · The Lancet · 2002 · 2K citations

Breast Oncology, Early Breast Cancer, Medicine +10

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

W. Fraser Symmans, Florentia Peintinger, Christos Hatzis et al. · Journal of Clinical Oncology · 2007 · 1.6K citations · Full text

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Henry M. Kuerer, Lisa A. Newman, Terry L. Smith et al. · Journal of Clinical Oncology · 1999 · 1.3K citations

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Breast Oncology, Oncology, Pathology +5